Benitec Biopharma (BNTC) Competitors $13.80 -0.29 (-2.06%) Closing price 04:00 PM EasternExtended Trading$13.75 -0.05 (-0.36%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTC vs. JANX, COGT, SDGR, SNDX, ABCL, AMPH, STOK, TLRY, EVO, and RCUSShould you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Janux Therapeutics (JANX), Cogent Biosciences (COGT), Schrodinger (SDGR), Syndax Pharmaceuticals (SNDX), AbCellera Biologics (ABCL), Amphastar Pharmaceuticals (AMPH), Stoke Therapeutics (STOK), Tilray Brands (TLRY), Evotec (EVO), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Benitec Biopharma vs. Its Competitors Janux Therapeutics Cogent Biosciences Schrodinger Syndax Pharmaceuticals AbCellera Biologics Amphastar Pharmaceuticals Stoke Therapeutics Tilray Brands Evotec Arcus Biosciences Benitec Biopharma (NASDAQ:BNTC) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings. Do institutionals & insiders believe in BNTC or JANX? 52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by insiders. Comparatively, 8.1% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, BNTC or JANX? Benitec Biopharma has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.84, meaning that its stock price is 184% more volatile than the S&P 500. Do analysts rate BNTC or JANX? Benitec Biopharma presently has a consensus price target of $24.80, indicating a potential upside of 79.71%. Janux Therapeutics has a consensus price target of $78.31, indicating a potential upside of 259.70%. Given Janux Therapeutics' higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.06 Is BNTC or JANX more profitable? Janux Therapeutics' return on equity of -11.48% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -46.19% -43.88% Janux Therapeutics N/A -11.48%-11.01% Does the media refer more to BNTC or JANX? In the previous week, Benitec Biopharma had 14 more articles in the media than Janux Therapeutics. MarketBeat recorded 17 mentions for Benitec Biopharma and 3 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.66 beat Benitec Biopharma's score of 0.58 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, BNTC or JANX? Benitec Biopharma has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec Biopharma$80K4,528.13-$21.75M-$1.47-9.39Janux Therapeutics$10.59M123.53-$68.99M-$1.80-12.09 SummaryJanux Therapeutics beats Benitec Biopharma on 10 of the 16 factors compared between the two stocks. Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTC vs. The Competition Export to ExcelMetricBenitec BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$369.87M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.77%4.64%P/E Ratio-9.397.5757.3222.37Price / Sales4,528.13442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book2.959.6212.876.30Net Income-$21.75M-$52.73M$3.29B$271.03M7 Day Performance-1.36%0.64%-0.26%-0.15%1 Month Performance4.47%6.31%3.84%6.41%1 Year Performance56.82%18.97%68.35%28.81% Benitec Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTCBenitec Biopharma1.6976 of 5 stars$13.80-2.1%$24.80+79.7%+57.6%$369.87M$80K-9.3920Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionJANXJanux Therapeutics2.3911 of 5 stars$23.56-2.0%$80.92+243.4%-53.0%$1.45B$10.59M-13.0930COGTCogent Biosciences2.3858 of 5 stars$12.41-2.0%$20.00+61.2%+21.1%$1.44BN/A-6.9780SDGRSchrodinger3.2013 of 5 stars$18.46-0.6%$27.83+50.8%+0.8%$1.37B$237.92M-7.44790SNDXSyndax Pharmaceuticals3.9034 of 5 stars$15.84+1.9%$39.22+147.6%-17.9%$1.34B$23.68M-4.07110ABCLAbCellera Biologics2.897 of 5 stars$4.35-2.7%$8.00+83.9%+89.3%$1.34B$32.88M-7.91500Positive NewsAMPHAmphastar Pharmaceuticals4.2837 of 5 stars$27.27-2.8%$31.60+15.9%-43.3%$1.30B$731.97M10.212,028Positive NewsSTOKStoke Therapeutics3.9125 of 5 stars$23.40-0.3%$25.57+9.3%+77.7%$1.29B$199.89M27.53100Positive NewsTLRYTilray Brands2.6277 of 5 stars$1.18+5.4%$1.94+64.2%-26.7%$1.23B$210.48M-0.512,842Gap DownEVOEvotec1.5762 of 5 stars$3.50+0.9%$5.40+54.3%+10.1%$1.23B$777.33M0.004,827Gap DownRCUSArcus Biosciences1.61 of 5 stars$11.57+0.4%$21.14+82.7%-19.6%$1.23B$262M-3.65500Positive News Related Companies and Tools Related Companies JANX Alternatives COGT Alternatives SDGR Alternatives SNDX Alternatives ABCL Alternatives AMPH Alternatives STOK Alternatives TLRY Alternatives EVO Alternatives RCUS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTC) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BNTC Stock Alerts